Last reviewed · How we verify
Betaseron
At a glance
| Generic name | Betaseron |
|---|---|
| Also known as | Betaseron 250 mcg SQ every other day, Intaferon beta 1 b |
| Sponsor | University of Medicine and Dentistry of New Jersey |
| Target | Interferon alpha/beta receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Relapsing remitting multiple sclerosis
Common side effects
- Injection site reaction
- Lymphocytes count decreased (<1500/mm3)
- Flu-like symptoms
- Asthenia
- Headache
- Hypertonia
- Pain
- Myalgia
- Fever
- Rash
- Insomnia
- Chills
Serious adverse events
- Injection site necrosis
- Absolute neutrophil count decreased
- White blood cell count decreased
- Lymphadenopathy
- Hypertension
- Dyspnea
- Aspartate aminotransferase increased
- Impotence
- Malaise
Key clinical trials
- An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (PHASE4)
- US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
- Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
- Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) (PHASE2)
- Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation (PHASE2, PHASE3)
- Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betaseron CI brief — competitive landscape report
- Betaseron updates RSS · CI watch RSS
- University of Medicine and Dentistry of New Jersey portfolio CI